Candid Therapeutics launches first-in-class T-cell engager trials across five autoimmune diseases

Candid Therapeutics, a clinical-stage biotechnology company based in San Diego, has begun early-stage trials of its bispecific antibody drugs—cizutamig and CND261—in five autoimmune diseases. Both candidates are T-cell engagers (TCEs) initially developed for oncology but now being tested in immune-mediated conditions such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, IgA nephropathy, and myasthenia gravis.

Founded in 2024, Candid Therapeutics raised $370 million at launch to accelerate its novel immunology pipeline. The American biotech company’s focus lies in harnessing TCEs to selectively deplete B-cells driving chronic autoimmune disorders, leveraging oncology-derived drug constructs with optimized safety and subcutaneous delivery formats. Early patient dosing has now commenced in refractory cases, accompanied by clinical signs of activity and tolerability.

Institutional sentiment toward the emerging autoimmune TCE class is building, as investors look beyond anti-TNF biologics toward next-generation B-cell targeting platforms that could offer deeper, more selective depletion without generalized immune suppression.

What clinical indications are Candid Therapeutics targeting with its lead BCMA and CD20 T-cell engagers?

Candid Therapeutics has initiated clinical trials in five high-burden autoimmune conditions—rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus, myasthenia gravis, and IgA nephropathy. These diseases are united by pathogenic B-cell activity, and both cizutamig and CND261 are designed to engage CD3 on T-cells and corresponding B-cell markers (BCMA and CD20, respectively), enabling targeted cytotoxicity.

Initial trial dosing has begun for cizutamig in systemic sclerosis and for CND261 in refractory rheumatoid arthritis, with subcutaneous administration formats already validated. According to company disclosures, both candidates have demonstrated early tolerability and signs of clinical response, though detailed efficacy readouts remain pending.

Each clinical program will assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and initial signs of efficacy across their respective indications. Additional studies are planned for the second half of 2025, potentially expanding into other autoimmune disorders where B-cell depletion has shown therapeutic promise.

These programs represent the first major autoimmune applications of T-cell engagers, which have traditionally been confined to oncology due to immune activation risks. Candid Therapeutics is betting that rational engineering—such as lowering CD3 affinity in CND261—can mitigate safety concerns while preserving potent and selective depletion.

How do cizutamig and CND261 differ from existing autoimmune therapies on the market?

Cizutamig is a bispecific antibody that binds B-cell maturation antigen (BCMA) and CD3, while CND261 targets CD20 and CD3. In both cases, the goal is to recruit T-cells to eliminate B-cells through direct cytotoxicity. This represents a departure from established agents like rituximab, which mediate antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) indirectly.

The American biotech company has adapted these TCEs from oncology into immunology by modifying T-cell binding affinity and delivery format. Cizutamig, which showed efficacy in multiple myeloma settings, is now being evaluated for autoimmune disorders where long-lived BCMA+ plasma cells are implicated in chronic disease. CND261 has been engineered with low CD3 affinity to reduce systemic immune activation, a crucial adjustment for long-term autoimmune treatment.

This next-generation approach aims to achieve deeper and more sustained B-cell depletion compared to anti-CD20 monoclonal antibodies, which may leave pathogenic memory B-cells or plasmablasts intact. Furthermore, the use of subcutaneous dosing facilitates outpatient administration and potentially reduces the cost and burden of care.

Analysts believe that TCEs—if shown to be safe in chronic indications—could outpace TNF inhibitors in long-term commercial potential, particularly given the growing biologic penetration across immune-mediated diseases.

What infrastructure has Candid Therapeutics built to support global trial execution and clinical scale-up?

Candid Therapeutics has completed core Chemistry, Manufacturing, and Controls (CMC) infrastructure to support global development. The biotech has finalized multiple clinical-grade manufacturing runs of both cizutamig and CND261 and established subcutaneous formulations for both agents.

These CMC activities are designed to accelerate international regulatory alignment and ensure consistent drug supply for multicenter trials. Candid Therapeutics has also established a fully operational legal entity in China, staffed with regulatory, clinical development, and trial operations professionals. This team is tasked with early clinical execution across the Asia-Pacific region, reinforcing the company’s global development ambition.

The American biotech company’s infrastructure investments reflect institutional confidence in TCE scalability, as well as the expectation of multi-indication expansion pending Phase 1 data readouts. Industry observers have noted the pace and parallelism of Candid Therapeutics’ program launches—an indicator of capital strength and operational maturity.

What is the institutional outlook on T-cell engagers in autoimmune therapy, and how is Candid Therapeutics positioned?

Institutional sentiment toward T-cell engagers in immunology has shifted from cautious curiosity to active interest, especially as data accumulates on their ability to provide deep, antigen-specific B-cell depletion without generalized immunosuppression. Candid Therapeutics is emerging as a first mover in this modality within autoimmune settings.

While most current TCE clinical data originates from hematologic malignancies, investors are increasingly watching for immunology-specific tolerability profiles and signs of durable disease control in chronic settings. The promise lies in TCEs’ ability to target long-lived B-cell subsets such as plasma cells and memory B-cells, which traditional therapies may spare.

Candid Therapeutics’ differentiated strategy—launching two TCEs simultaneously with tailored binding affinities and targeting profiles—gives it a platform-based advantage. With several autoimmune indications underway and more expected in 2025, institutional stakeholders see Candid as well-positioned to define the next chapter of targeted immune modulation.

While unlisted, the company’s $370 million launch financing from life science investors signals confidence in both its scientific approach and commercial opportunity. Analysts believe that successful proof-of-concept data could open doors for partnerships or further private capital raises, particularly as large-cap biopharma companies look to refill immunology pipelines.

What milestones can investors and industry observers expect from Candid Therapeutics in the coming quarters?

Candid Therapeutics anticipates additional trial initiations, global site activations, and interim data readouts over the coming quarters. Phase 1 safety and PK/PD data from early cohorts in rheumatoid arthritis and systemic sclerosis are expected to lay the groundwork for expanded dose-ranging and efficacy studies.

The American biotech company is also preparing for broader indication launches, including potential new studies in autoimmune dermatology, gastrointestinal disorders, and renal diseases. Future readouts will likely inform registrational strategy, subpopulation targeting, and combination therapy design.

Institutional analysts expect that if tolerability thresholds are maintained, the TCE modality could shift into Phase 2 proof-of-concept trials by early 2026. Regulatory feedback from the FDA and ex-U.S. agencies, particularly in China, will also be key milestones given the company’s international execution model.

Given its funding reserves, CMC readiness, and dual-agent platform, Candid Therapeutics is now viewed as a clinical-stage innovator to watch in the evolving immunology drug landscape. Its future performance could shape investor sentiment across the broader TCE class, especially if B-cell depleting strategies continue to gain traction in diseases beyond oncology.